用于治疗抗癌药物超敏反应的奥马珠单抗。

IF 1.8 4区医学 Q2 MEDICINE, GENERAL & INTERNAL Internal Medicine Journal Pub Date : 2024-07-19 DOI:10.1111/imj.16464

Piyush Grover, Matthew Krummenacher, Timothy Loy, Anna K. Nowak, Michaela Lucas

{"title":"用于治疗抗癌药物超敏反应的奥马珠单抗。","authors":"Piyush Grover, Matthew Krummenacher, Timothy Loy, Anna K. Nowak, Michaela Lucas","doi":"10.1111/imj.16464","DOIUrl":null,"url":null,"abstract":"<p>Hypersensitivity reactions to anticancer drugs include treatment-limiting toxicity. Standard drug desensitisation offers temporary tolerance and hence requires repetition. We used omalizumab, an anti-immunoglobulin E antibody, to overcome immediate and delayed hypersensitivity reactions to various anticancer drugs. Seven of the eight patients in the current study successfully resumed the desired anticancer drug regimen without standard desensitisation. No safety issues from omalizumab were observed.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":"54 8","pages":"1396-1400"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imj.16464","citationCount":"0","resultStr":"{\"title\":\"Omalizumab for management of hypersensitivity reactions to anticancer drugs\",\"authors\":\"Piyush Grover, Matthew Krummenacher, Timothy Loy, Anna K. Nowak, Michaela Lucas\",\"doi\":\"10.1111/imj.16464\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Hypersensitivity reactions to anticancer drugs include treatment-limiting toxicity. Standard drug desensitisation offers temporary tolerance and hence requires repetition. We used omalizumab, an anti-immunoglobulin E antibody, to overcome immediate and delayed hypersensitivity reactions to various anticancer drugs. Seven of the eight patients in the current study successfully resumed the desired anticancer drug regimen without standard desensitisation. No safety issues from omalizumab were observed.</p>\",\"PeriodicalId\":13625,\"journal\":{\"name\":\"Internal Medicine Journal\",\"volume\":\"54 8\",\"pages\":\"1396-1400\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imj.16464\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internal Medicine Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/imj.16464\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imj.16464","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

抗癌药物的过敏反应包括限制治疗的毒性。标准的药物脱敏疗法只能提供暂时的耐受性，因此需要重复使用。我们使用抗免疫球蛋白 E 抗体奥马珠单抗来克服对各种抗癌药物的即刻和延迟超敏反应。在本次研究中，八名患者中有七名成功恢复了所需的抗癌药物治疗方案，而无需进行标准的脱敏治疗。没有观察到奥马珠单抗的安全性问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Omalizumab for management of hypersensitivity reactions to anticancer drugs

Hypersensitivity reactions to anticancer drugs include treatment-limiting toxicity. Standard drug desensitisation offers temporary tolerance and hence requires repetition. We used omalizumab, an anti-immunoglobulin E antibody, to overcome immediate and delayed hypersensitivity reactions to various anticancer drugs. Seven of the eight patients in the current study successfully resumed the desired anticancer drug regimen without standard desensitisation. No safety issues from omalizumab were observed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Internal Medicine Journal 医学-医学：内科

CiteScore

3.50

自引率

4.80%

发文量

600

审稿时长

3-6 weeks

期刊介绍： The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.